Vertical Soft Tissue Augmentation With CTG vs ADM
Vertical Soft Tissue Augmentation With Dermal Matrix and Enamel Matrix Derivative vs Connective Tissue Graft for the Treatment of Peri-implant Soft Tissue Dehiscences in the Esthetic Zone: A Randomized, Controlled, Clinical, Trial
Harvard Medical School (HMS and HSDM)
28 participants
May 26, 2023
INTERVENTIONAL
Conditions
Summary
The study aims at comparing two different approaches for vertical soft tissue augmentation at implant sites exhibiting soft tissue dehiscences: autogenous connective tissue graft vs acellular dermal matrix + enamel matrix derivative
Eligibility
Inclusion Criteria5
- Age ≥ 18 years
- Periodontally and systemically healthy
- Full-mouth plaque score and full-mouth bleeding score ≤ 20% (measured at four sites per tooth)
- Presence of single functional dental implant in the anterior with a PSTD
- Implants diagnosed as healthy (Berglundh et al., 2018)
Exclusion Criteria7
- Contraindications for surgery
- Systemic condition (e.g. diabetes mellitus, HIV, cancer, etc) that could compromise wound healing
- Patients pregnant or attempting to get pregnant (self-reported)
- Untreated periodontitis
- Untreated peri-implant mucositis or peri-implantitis (Berglundh et al., 2018)
- Smoking, defined as self-reported daily habit. Occasional smokers won't be excluded
- History of soft tissue grafting at the implant site within the last 6 months
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Vertical soft tissue augmentation with autogenous connective tissue graft (CTG)
Vertical soft tissue augmentation with acellular dermal matrix (ADM) and enamel matrix derivative (EMD)
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05729607